We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more
false 0001840439 0001840439 2024-03-06 2024-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT...
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2...
REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
4th Floor false 0001840439 0001840439 2024-01-09 2024-01-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT...
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.05 | -6.5625 | 16 | 17.25 | 14.7 | 737955 | 15.8144053 | CS |
4 | -4.05 | -21.3157894737 | 19 | 19.3549 | 14.24 | 1323109 | 16.52305561 | CS |
12 | 0.15 | 1.01351351351 | 14.8 | 20.21 | 13.4407 | 979690 | 16.66578051 | CS |
26 | 1.23 | 8.96501457726 | 13.72 | 22.74 | 8.125 | 1067354 | 15.12082149 | CS |
52 | -8.05 | -35 | 23 | 43.69 | 8.125 | 1002203 | 20.98010042 | CS |
156 | -5.05 | -25.25 | 20 | 43.69 | 2.84 | 430254 | 18.80176141 | CS |
260 | -5.05 | -25.25 | 20 | 43.69 | 2.84 | 430254 | 18.80176141 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions